Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/46288
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | - |
dc.contributor.author | GIOVANINI, Guilherme | - |
dc.contributor.author | BARROS, Luciana R. C. | - |
dc.contributor.author | GAMA, Leonardo R. | - |
dc.contributor.author | TORTELLI, Tharcisio C. | - |
dc.contributor.author | RAMOS, Alexandre F. | - |
dc.date.accessioned | 2022-04-19T13:12:27Z | - |
dc.date.available | 2022-04-19T13:12:27Z | - |
dc.date.issued | 2022 | - |
dc.identifier.citation | CANCERS, v.14, n.3, article ID 633, 29p, 2022 | - |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/46288 | - |
dc.description.abstract | Simple Summary Gene editing technologies reached a turning point toward epigenetic modulation for cancer treatment. Gene networks are complex systems composed of multiple non-trivially coupled elements capable of reliably processing dynamical information from the environment despite unavoidable randomness. However, this functionality is lost when the cells are in a diseased state. Hence, gene-editing-based therapeutic design can be viewed as a gene network dynamics modulation toward a healthy state. Enhancement of this control relies on mathematical models capable of effectively describing the regulation of stochastic gene expression. We use a two-state stochastic model for gene expression to investigate treatment response with a switching target gene. We show the necessity of modulating multiple gene-expression-related processes to reach a heterogeneity-reduced specific response using epigenetic-targeting cancer treatment designs. Our approach can be used as an additional tool for developing epigenetic-targeting treatments. In this manuscript, we use an exactly solvable stochastic binary model for the regulation of gene expression to analyze the dynamics of response to a treatment aiming to modulate the number of transcripts of a master regulatory switching gene. The challenge is to combine multiple processes with different time scales to control the treatment response by a switching gene in an unavoidable noisy environment. To establish biologically relevant timescales for the parameters of the model, we select the RKIP gene and two non-specific drugs already known for changing RKIP levels in cancer cells. We demonstrate the usefulness of our method simulating three treatment scenarios aiming to reestablish RKIP gene expression dynamics toward a pre-cancerous state: (1) to increase the promoter's ON state duration; (2) to increase the mRNAs' synthesis rate; and (3) to increase both rates. We show that the pre-treatment kinetic rates of ON and OFF promoter switching speeds and mRNA synthesis and degradation will affect the heterogeneity and time for treatment response. Hence, we present a strategy for reaching increased average mRNA levels with diminished heterogeneity while reducing drug dosage by simultaneously targeting multiple kinetic rates that effectively represent the chemical processes underlying the regulation of gene expression. The decrease in heterogeneity of treatment response by a target gene helps to lower the chances of emergence of resistance. Our approach may be useful for inferring kinetic constants related to the expression of antimetastatic genes or oncogenes and for the design of multi-drug therapeutic strategies targeting the processes underpinning the expression of master regulatory genes. | eng |
dc.language.iso | eng | - |
dc.publisher | MDPI | eng |
dc.relation.ispartof | Cancers | - |
dc.rights | openAccess | eng |
dc.subject | epigenetic regulation in cancer treatment | eng |
dc.subject | stochastic binary regulation of gene expression | eng |
dc.subject | treatment targeting RKIP levels | eng |
dc.subject | reduction of heterogeneity of treatment response | eng |
dc.subject | gene therapy | eng |
dc.subject | multi-drug therapy | eng |
dc.subject.other | raf kinase inhibitor | eng |
dc.subject.other | breast-cancer cells | eng |
dc.subject.other | nf-kappa-b | eng |
dc.subject.other | nitric-oxide | eng |
dc.subject.other | protein rkip | eng |
dc.subject.other | prostate-cancer | eng |
dc.subject.other | synergistic cytotoxicity | eng |
dc.subject.other | mesenchymal transition | eng |
dc.subject.other | aberrant methylation | eng |
dc.subject.other | sensitizes prostate | eng |
dc.title | A Stochastic Binary Model for the Regulation of Gene Expression to Investigate Responses to Gene Therapy | eng |
dc.type | article | eng |
dc.rights.holder | Copyright MDPI | eng |
dc.identifier.doi | 10.3390/cancers14030633 | - |
dc.identifier.pmid | 35158901 | - |
dc.subject.wos | Oncology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | GIOVANINI, Guilherme:Univ Sao Paulo, Escola Artes Ciencias & Humanidades, Av Arlindo Bettio 1000, BR-03828000 Sao Paulo, SP, Brazil | - |
hcfmusp.description.articlenumber | 633 | - |
hcfmusp.description.issue | 3 | - |
hcfmusp.description.volume | 14 | - |
hcfmusp.origem | WOS | - |
hcfmusp.origem.id | WOS:000756401500001 | - |
hcfmusp.origem.id | 2-s2.0-85123441300 | - |
hcfmusp.publisher.city | BASEL | eng |
hcfmusp.publisher.country | SWITZERLAND | eng |
hcfmusp.relation.reference | Abramowitz M, 1972, APPL MATH SERIES, V55 | eng |
hcfmusp.relation.reference | Al-Mulla F, 2011, CANCER RES, V71, P1334, DOI 10.1158/0008-5472.CAN-10-3102 | eng |
hcfmusp.relation.reference | Alizadeh AA, 2015, NAT MED, V21, P846, DOI 10.1038/nm.3915 | eng |
hcfmusp.relation.reference | Arfken G.B., 2005, MATH METHODS PHYS, V6 | eng |
hcfmusp.relation.reference | Balazsi G, 2011, CELL, V144, P910, DOI 10.1016/j.cell.2011.01.030 | eng |
hcfmusp.relation.reference | Baritaki S, 2010, CELL CYCLE, V9, P4931, DOI 10.4161/cc.9.24.14229 | eng |
hcfmusp.relation.reference | Beach S, 2008, ONCOGENE, V27, P2243, DOI 10.1038/sj.onc.1210860 | eng |
hcfmusp.relation.reference | Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381 | eng |
hcfmusp.relation.reference | Bonavida B, 2021, CRIT REV ONCOGENESIS, DOI [10.1615/CritRevOncog.2021035853, DOI 10.1615/CRITREVONCOG.2021035853] | eng |
hcfmusp.relation.reference | Bonavida B., 2020, PROGNOSTIC THERAPEUT, DOI [10.1016/C2019-0-00062-3, DOI 10.1016/C2019-0-00062-3] | eng |
hcfmusp.relation.reference | Bonavida Benjamin, 2014, Critical Reviews in Oncogenesis, V19, P431 | eng |
hcfmusp.relation.reference | Bonavida Benjamin, 2011, Critical Reviews in Oncogenesis, V16, P211 | eng |
hcfmusp.relation.reference | Brock A, 2015, NAT REV CANCER, V15, P499, DOI 10.1038/nrc3959 | eng |
hcfmusp.relation.reference | Bulaklak K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19505-2 | eng |
hcfmusp.relation.reference | Cai WW, 2020, PEERJ, V8, DOI 10.7717/peerj.9952 | eng |
hcfmusp.relation.reference | Chatterjee D, 2004, J BIOL CHEM, V279, P17515, DOI 10.1074/jbc.M313816200 | eng |
hcfmusp.relation.reference | Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200 | eng |
hcfmusp.relation.reference | Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294 | eng |
hcfmusp.relation.reference | Datar Ila, 2014, Critical Reviews in Oncogenesis, V19, P417 | eng |
hcfmusp.relation.reference | De Castro J., 2020, PROGNOSTIC THERAPEUT, P139, DOI 10.1016/B978-0-12-819612-0.00009-2 | eng |
hcfmusp.relation.reference | Delbruck M., 1940, J CHEM PHYS, V8, P120, DOI [10.1063/1.1750549, DOI 10.1063/1.1750549] | eng |
hcfmusp.relation.reference | Deng X, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44313-0 | eng |
hcfmusp.relation.reference | Du Y, 2017, ONCOTARGET, V8, P94358, DOI 10.18632/oncotarget.21719 | eng |
hcfmusp.relation.reference | Du Y, 2017, CELL PHYSIOL BIOCHEM, V41, P1135, DOI 10.1159/000464120 | eng |
hcfmusp.relation.reference | Ferrell JE, 2016, CELL SYST, V2, P62, DOI 10.1016/j.cels.2016.02.006 | eng |
hcfmusp.relation.reference | Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878 | eng |
hcfmusp.relation.reference | Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319 | eng |
hcfmusp.relation.reference | Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910 | eng |
hcfmusp.relation.reference | Galal Y., 2021, SUCCESSES CHALLENGES, P233, DOI 10.1016/B978-0-12-824375-6.00012-6 | eng |
hcfmusp.relation.reference | Gama LR, 2020, ENTROPY-SWITZ, V22, DOI 10.3390/e22040479 | eng |
hcfmusp.relation.reference | Gerard C, 2019, J THEOR BIOL, V461, P276, DOI 10.1016/j.jtbi.2018.10.042 | eng |
hcfmusp.relation.reference | Giovanini G, 2020, MATH BIOSCI ENG, V17, P5477, DOI 10.3934/mbe.2020295 | eng |
hcfmusp.relation.reference | Giovannetti E, 2013, CURR PHARM DESIGN, V19, P927, DOI 10.2174/138161213804547268 | eng |
hcfmusp.relation.reference | Guinn MT, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.586726 | eng |
hcfmusp.relation.reference | Guo W, 2012, CANCER INVEST, V30, P703, DOI 10.3109/07357907.2012.732164 | eng |
hcfmusp.relation.reference | Hampl V, 1996, CARDIOVASC RES, V31, P55, DOI 10.1016/S0008-6363(95)00172-7 | eng |
hcfmusp.relation.reference | Hao CF, 2012, TUMOR BIOL, V33, P1159, DOI 10.1007/s13277-012-0358-7 | eng |
hcfmusp.relation.reference | Hays E, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090407 | eng |
hcfmusp.relation.reference | Hou WH, 2008, BBA-GENE REGUL MECH, V1779, P195, DOI 10.1016/j.bbagrm.2008.01.006 | eng |
hcfmusp.relation.reference | Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655 | eng |
hcfmusp.relation.reference | Innocentini GCP, 2007, J MATH BIOL, V55, P413, DOI 10.1007/s00285-007-0090-x | eng |
hcfmusp.relation.reference | Iyer-Biswas S, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.031911 | eng |
hcfmusp.relation.reference | Jarrett AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051314 | eng |
hcfmusp.relation.reference | Kim GE, 2017, APPL IMMUNOHISTO M M, V25, P467, DOI 10.1097/PAI.0000000000000323 | eng |
hcfmusp.relation.reference | Labbozzetta M, 2015, ONCOL LETT, V10, P3807, DOI 10.3892/ol.2015.3787 | eng |
hcfmusp.relation.reference | Lamiman Kelly, 2014, Critical Reviews in Oncogenesis, V19, P455 | eng |
hcfmusp.relation.reference | Lee J, 2014, P NATL ACAD SCI USA, V111, pE364, DOI 10.1073/pnas.1304840111 | eng |
hcfmusp.relation.reference | Lee TY, 2016, ONCOTARGET, V7, P23512, DOI 10.18632/oncotarget.8049 | eng |
hcfmusp.relation.reference | Lei XH, 2015, INT J CLIN EXP PATHO, V8, P14214 | eng |
hcfmusp.relation.reference | Levine JH, 2013, SCIENCE, V342, P1193, DOI 10.1126/science.1239999 | eng |
hcfmusp.relation.reference | Li DX, 2014, EXP THER MED, V8, P844, DOI 10.3892/etm.2014.1833 | eng |
hcfmusp.relation.reference | Lin Kimberly, 2010, Genes Cancer, V1, P409 | eng |
hcfmusp.relation.reference | Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158 | eng |
hcfmusp.relation.reference | Martinho O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059104 | eng |
hcfmusp.relation.reference | Martinho O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030769 | eng |
hcfmusp.relation.reference | Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261 | eng |
hcfmusp.relation.reference | Michor F, 2015, CELL, V163, P1059, DOI 10.1016/j.cell.2015.11.002 | eng |
hcfmusp.relation.reference | Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859 | eng |
hcfmusp.relation.reference | Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8 | eng |
hcfmusp.relation.reference | Morozova N, 2012, RNA, V18, P1635, DOI 10.1261/rna.032284.112 | eng |
hcfmusp.relation.reference | Pasqualetti G, 2011, LUNG CANCER, V74, P197, DOI 10.1016/j.lungcan.2011.03.003 | eng |
hcfmusp.relation.reference | PECCOUD J, 1995, THEOR POPUL BIOL, V48, P222, DOI 10.1006/tpbi.1995.1027 | eng |
hcfmusp.relation.reference | Pervin S, 2013, BRIT J CANCER, V108, P848, DOI 10.1038/bjc.2013.40 | eng |
hcfmusp.relation.reference | Pervin S, 2007, CANCER RES, V67, P289, DOI 10.1158/0008-5472.CAN-05-4623 | eng |
hcfmusp.relation.reference | Purvis JE, 2013, CELL, V152, P945, DOI 10.1016/j.cell.2013.02.005 | eng |
hcfmusp.relation.reference | Ramos AF, 2010, IET SYST BIOL, V4, P311, DOI 10.1049/iet-syb.2010.0058 | eng |
hcfmusp.relation.reference | Ramos A.F., 2020, PROGNOSTIC THERAPEUT, P257, DOI [10.1016/b978-0-12-819612-0.00014-6, DOI 10.1016/B978-0-12-819612-0.00014-6] | eng |
hcfmusp.relation.reference | Ramos AF, 2019, J CHEM PHYS, V151, DOI 10.1063/1.5105361 | eng |
hcfmusp.relation.reference | Rapozzi V, 2015, REDOX BIOL, V6, P311, DOI 10.1016/j.redox.2015.07.015 | eng |
hcfmusp.relation.reference | Rapozzi V, 2013, NITRIC OXIDE-BIOL CH, V30, P26, DOI 10.1016/j.niox.2013.01.002 | eng |
hcfmusp.relation.reference | Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546 | eng |
hcfmusp.relation.reference | Ricciardi S, 2010, CHEMOTHERAPY, V56, P303, DOI 10.1159/000320031 | eng |
hcfmusp.relation.reference | Schuierer MM, 2004, CANCER RES, V64, P5186, DOI 10.1158/0008-5472.CAN-03-3861 | eng |
hcfmusp.relation.reference | Shahrezaei V, 2008, P NATL ACAD SCI USA, V105, P17256, DOI 10.1073/pnas.0803850105 | eng |
hcfmusp.relation.reference | Shvartsur A, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0535-z | eng |
hcfmusp.relation.reference | Thakore PI, 2016, NAT METHODS, V13, P127, DOI [10.1038/NMETH.3733, 10.1038/nmeth.3733] | eng |
hcfmusp.relation.reference | Trakul N, 2005, J BIOL CHEM, V280, P24931, DOI 10.1074/jbc.M413929200 | eng |
hcfmusp.relation.reference | Walker Evan J, 2011, For Immunopathol Dis Therap, V2, P195 | eng |
hcfmusp.relation.reference | Wei H, 2017, ONCOL LETT, V13, P1866, DOI 10.3892/ol.2017.5617 | eng |
hcfmusp.relation.reference | Welch DR, 2016, CANCER RES, V76, P4, DOI 10.1158/0008-5472.CAN-15-3024 | eng |
hcfmusp.relation.reference | Wink DA, 2008, NITRIC OXIDE-BIOL CH, V19, P65, DOI 10.1016/j.niox.2008.05.003 | eng |
hcfmusp.relation.reference | Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037 | eng |
hcfmusp.relation.reference | Wu XH, 2016, BBA-GEN SUBJECTS, V1860, P384, DOI 10.1016/j.bbagen.2015.06.009 | eng |
hcfmusp.relation.reference | Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846 | eng |
hcfmusp.relation.reference | Yesilkanal AE, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101128 | eng |
hcfmusp.relation.reference | Yesilkanal Ali E., 2014, Critical Reviews in Oncogenesis, V19, P447 | eng |
hcfmusp.relation.reference | Yesilkanal AE, 2021, ELIFE, V10, DOI 10.7554/eLife.59696 | eng |
hcfmusp.relation.reference | Yesilkanal AE, 2018, CANCERS, V10, DOI 10.3390/cancers10090306 | eng |
hcfmusp.relation.reference | Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686 | eng |
hcfmusp.relation.reference | Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001 | eng |
hcfmusp.relation.reference | Yousuf S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092478 | eng |
hcfmusp.relation.reference | Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312 | eng |
hcfmusp.relation.reference | Zaravinos A, 2018, CANCERS, V10, DOI 10.3390/cancers10090287 | eng |
hcfmusp.relation.reference | Zhao DQ, 2013, ONCOL REP, V30, P304, DOI 10.3892/or.2013.2464 | eng |
hcfmusp.relation.reference | Zhao Jinming, 2014, Critical Reviews in Oncogenesis, V19, P497 | eng |
hcfmusp.relation.reference | Zou QY, 2016, ARCH BIOCHEM BIOPHYS, V610, P25, DOI 10.1016/j.abb.2016.09.007 | eng |
dc.description.index | PubMed | eng |
dc.identifier.eissn | 2072-6694 | - |
hcfmusp.citation.scopus | 3 | - |
hcfmusp.scopus.lastupdate | 2024-04-12 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_GIOVANINI_A_Stochastic_Binary_Model_for_the_Regulation_of_2022.PDF | publishedVersion (English) | 1.6 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.